Robert W. Baird analyst Colleen M. Kusy maintained a Hold rating on Mersana Therapeutics (MRSN – Research Report) on August 9 and set a price target of $1.00. The company’s shares opened today at $1.18.
M. Kusy covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, EyePoint Pharmaceuticals, and Iovance Biotherapeutics. According to TipRanks, M. Kusy has an average return of -22.4% and a 25.99% success rate on recommended stocks.
In addition to Robert W. Baird, Mersana Therapeutics also received a Hold from Citi’s Ashiq Mubarack in a report issued on July 27. However, on August 2, J.P. Morgan downgraded Mersana Therapeutics (NASDAQ: MRSN) to a Sell.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $9.62 and a one-year low of $0.80. Currently, Mersana Therapeutics has an average volume of 7.54M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC); and XMT-1536, which targets ovarian cancer and NSCLC. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
Read More on MRSN:
- Mersana Therapeutics Announces Second Quarter 2023 Financial Results
- Mersana Therapeutics reports Q2 EPS (47c), consensus (44c)
- Is MRSN a Buy, Before Earnings?
- Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Block upgraded, Southwest downgraded: Wall Street’s top analyst calls
